{"id":"W4415451907","doi":"10.1016/j.cllc.2025.10.018","title":"Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Epidermal growth factor receptor; Placebo; Biomarker; Epidermal growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001586861,0.002572989,0.003066777,0.0004163446,0.0004375137,0.001641761,0.0008937236,0.001731065,0.005841722],"category_scores_gemma":[0.001143701,0.0007566047,0.002311789,0.0004849884,0.00139946,0.00153315,0.0004287239,0.003841522,0.001202728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001130387,"about_ca_system_score_gemma":0.001310933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001176663,"about_ca_topic_score_gemma":0.003060606,"domain_scores_codex":[0.9995019,0.0002121888,0.00002707586,0.0001016994,0.00004000453,0.0001170198],"domain_scores_gemma":[0.9994837,0.0001203402,0.00009548732,0.00004170848,0.00003182773,0.0002269101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9702459,0.005689531,0.000900005,0.0005635472,0.00131912,0.00006124313,0.00007121306,0.0008265923,0.003309098,0.0002375406,0.001407715,0.01536854],"study_design_scores_gemma":[0.9435844,0.05267214,0.001245766,0.00002412901,0.0005019034,0.00004494539,0.0000350401,0.0005673502,0.0003240309,0.0002250669,0.0007587732,0.00001645735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871008,0.004754335,0.0006308949,0.0008536964,0.0006638495,0.002317252,0.00103987,0.0001341814,0.00250504],"genre_scores_gemma":[0.9844474,0.003309672,0.001144747,0.001180586,0.0004385712,0.002793481,0.001794709,0.00004076684,0.004850025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005841722,"threshold_uncertainty_score":0.01954252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03420173911946064,"score_gpt":0.4352266216902665,"score_spread":0.4010248825708058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}